Danish Medicine's Agency declines two new reimbursements
This article was originally published in Scrip
Executive Summary
The Danish Medicines Agencyhas declined two drugs for general reimbursement: Sandoz's anti-inflammatory Migea Rapid (tolfenamic acid), andBasilea Pharmaceutica's eczema treatment Toctino (alitretinoin). Reimbursement decisions are based on Section 144 of the Danish Health Act. The Agency has now reimbursed 19 medicines and declined to reimburse five this year.